Practo, ZocDoc, Doctolib: Are a wave of Healthcare Appointment Booking IPOs on the Horizon?
- Nelson Advisors
- 6 days ago
- 14 min read
Industrial Maturity and the Generative Surge: A Strategic Analysis of the 2026 HealthTech IPO Wave
The global healthcare technology landscape has reached a definitive inflection point in 2026, transitioning from a period of speculative, venture-subsidised fragmentation into a disciplined era defined by industrial maturity and strategic consolidation. This transition is most visible in the anticipated wave of multi-billion dollar initial public offerings (IPOs) from category leaders such as ZocDoc, Doctolib and Practo.
After a market cooldown following the peak of the COVID-19 pandemic, momentum for health technology exits began returning in 2025, driven by a fundamental shift from growth-at-all-costs toward durability,
profitability, and clinical-grade evidence. The current market environment is characterized by an open but narrow window, where only high-performing companies with recalibrated valuations and clear paths to profitability are finding success in the public markets.
The broader macroeconomic environment in 2026 supports this activity, as interest rates stabilize and global GDP growth rebounds from the contractions seen in 2023 and 2024. However, a significant trust gap remains among public investors, who remember the volatility of the first generation of health tech stocks. Consequently, even high-performing 2026 candidates often trade at a 10% to 20% discount compared to high-growth software counterparts, despite underlying business metrics that frequently exceed those of traditional enterprise software-as-a-service (SaaS) companies.
The defining differentiator for the 2026 cohort is the integration of generative artificial intelligence (AI), which has matured beyond experimental pilots into embedded, system-wide deployments that meaningfully augment clinical and operational workflows.
Macroeconomic Context and the Reopening of the IPO Window
The global economy in 2026 is characterized by a shift in fiscal and structural policy as governments adapt to new geopolitical realities. In the United States, the investment climate is influenced by policy alignment and valuation resets. PitchBook analysis indicates that 2025 and 2026 IPOs have been concentrated in sectors prioritised by current administrative agendas, including AI, space technology, and defense. Healthcare and life sciences, while historically resilient, have faced unique headwinds due to pricing pressures and regulatory shifts, yet they remain a core pillar of the venture market's recovery.
The market has benefited from a necessary valuation reset, with widespread down-round IPOs allowing for a recalibration from pandemic-era peak pricing to today’s more sustainable levels. While 2025 saw improved liquidity conditions, the number of companies going public remained consistent with post-pandemic lows, pointing to a concentrated exit value rather than a full market recovery. For the venture market to find durable relief, a broader slate of large IPOs is required to generate market-wide liquidity.
Global IPO Activity and Sector Concentration (2025-2026)
Sector | Percentage of IPO Activity (2025) | Market Sentiment (2026) | Driver |
Artificial Intelligence | 28.4% | Hyper-Growth | Productivity gains and margin expansion |
Healthcare/Life Sciences | 22.1% | Cautiously Positive | Shift to "Health Tech 2.0" and durability |
Fintech | 15.2% | Stable | Recalibrated valuations and cost management |
Defense/Cybersecurity | 12.8% | High Growth | Geopolitical tensions and tech sovereignty |
Others (SaaS, Crypto, etc.) | 21.5% | Mixed | Selective interest in execution-driven models |
In Europe, the narrative is increasingly defined by tech sovereignty. The region’s reliance on foreign digital infrastructure, which accounts for nearly 80% of its total, is now viewed as a strategic risk. Consequently, government-backed capital and policy alignment have become decisive factors in where startups get funded.
The European tech workforce is growing faster than that of the United States, and a new generation of technical founders is translating deep research into commercial entities. This environment provides a robust backdrop for Doctolib’s anticipated listing, as it positions itself as a champion of European digital health autonomy.
ZocDoc: The Mature Incumbent and the Secondary Market Signal
ZocDoc, founded in 2007 and headquartered in New York, represents one of the most established players in the healthcare appointment booking sector. After navigating a challenging period around 2015, where the company generated $71 million in revenue but burned $43 million in cash, ZocDoc underwent a fundamental turnaround. By switching its business model to a per-booking transaction fee, the company reached EBITDA profitability in late 2019 and has reportedly remained profitable through 2026.
Despite this internal stability, ZocDoc’s valuation has experienced significant volatility in the private secondary markets. As of March 30, 2026, shares were valued at a price implying a 67.26% discount to its last primary round, a Series D raised in September 2021 at an $1.8 billion valuation. This discount reflects the broader market’s skepticism toward late-stage venture valuations set during the 2021 peak.
However, ZocDoc’s secondary market ROI has shown signs of recovery, returning +6.94% over a 90-day period in early 2026, supported by $43.82 million in transaction activity.
ZocDoc Financial History and Valuation Trends
Metric | Detail/Value | Context |
Foundation Year | 2007 | New York, NY |
Series D Valuation (2021) | $1.8 Billion | Last primary funding round |
Secondary Market Share Price (2026) | $11.99 | Three-month moving average |
Secondary Valuation Change | -67.26% | Since the 2021 last round |
Implied Revenue Multiple | 8.3x | As of March 30, 2026 |
Total Raised to Date | $569 Million | Across primary and secondary events |
Employee Count | 800 | Stable workforce as of 2026 |
ZocDoc’s strategic focus in 2026 is the integration of AI to optimise the patient-provider relationship. The company has launched an AI-informed patient report and is leveraging generative AI to handle non-clinical administrative tasks, which it identifies as an opportunity to reduce the estimated $600 billion to $1 trillion spent annually on healthcare administration in the United States. Patents held by the company, such as an aggregator system for enabling online access to encounter data from multiple disparate sources, highlight its technical moat in an increasingly crowded interoperability market.
ZocDoc’s predictions for 2026 emphasise the rise of consumer-driven models. Patients are increasingly choosing convenience over traditional providers for transactional care and are turning to AI tools for initial healthcare advice. The company’s "You've Got Options" national campaign underscores this shift, positioning ZocDoc as a comprehensive digital front door that unifies in-person care, telehealth, and pharmacy access.
Doctolib: Financial Architecture and the Decisive Path to Public Markets
Doctolib has achieved unicorn status as Europe’s leading e-health platform, serving patients across France, Germany, and Italy. The company’s financial narrative in 2026 is characterized by disciplined growth and a narrowing of losses, which management has established as a prerequisite for its anticipated transition to public markets. In fiscal year 2024, Doctolib reported an Annual Recurring Revenue (ARR) of €348 million, a 22.5% increase from the previous year. While this represents a deceleration from earlier years, the market has responded favorably to the company’s expanded suite of clinical and financial products, evidenced by a 42% surge in new ARR in the second half of 2024.
The path to enterprise-wide profitability is supported by a significant improvement in operational efficiency. Doctolib reduced its adjusted EBITDA losses from €87.1 million in 2023 to €53.8 million in 2024, a 38% improvement.Management forecasts reaching breakeven in 2025, aligning with projections from its $549 million Series G round in 2022.
Doctolib Strategic and Financial Projections (2024-2027)
Indicator | 2024 Actual | 2025 Forecast | 2026 Position/Goal |
ARR | €348.0M | ~€420.0M+ | $450M+ Run-Rate |
Adjusted EBITDA | -€53.8M | Breakeven | EBITDA Positive Trajectory |
R&D Investment | €115M | ~€130M | 30% of Revenue |
Gross Margin | 65% | 70%+ | 60%-80% Target |
Workforce (FTE) | 2,900 | ~3,500+ | Scaling AI/Product teams |
Est. IPO Valuation | - | - | $6B-$8B Range |
Doctolib is currently positioned as a category leader in waiting. While no official filing has been confirmed as of the first half of 2026, the company is reportedly discussing a significant secondary investment to allow existing shareholders to find liquidity. A central strategic dilemma remains the choice of listing venue. The deeper liquidity and higher valuation multiples available in US capital pools are driving discussions of a Delaware Flip, although listing in Europe remains a possibility to maintain its standing as a continental champion.
The integration of agentic AI is a cornerstone of Doctolib’s 2026 strategy. By shifting from assistive AI to systems that can independently handle multi-step revenue and clinical processes, Doctolib aims to achieve the high margins typical of enterprise SaaS. The company's recent acquisition of ambient voice technology (Typeless) and its focus on vertical integration into hospital software demonstrate its ambition to control the entire patient journey.
Practo: Profitable Growth and the Global Care Navigation Pivot
Practo, founded in 2008 and based in Bengaluru, India, has transformed from a domestic appointment booking tool into a global healthcare ecosystem. In early 2026, the company entered advanced talks to raise up to $125 million in a pre-IPO round at a $700 million valuation. This round, structured as a mix of equity and debt, is intended to fund international expansion and strategic acquisitions ahead of a planned market debut in 2027.
Practo’s financial performance has reached a milestone, reporting a positive operating EBITDA of ₹15 crore in fiscal year 2025, compared to a ₹17 crore loss in FY2024. Although revenue remained relatively flat at ₹234 crore, the shift to profitability signals operational maturity. The company has also achieved significant success in the US market, where it currently lists 200,000 doctors and reports a Gross Merchandise Value (GMV) run rate of over $75 million.
Practo Operational and Financial Metrics (FY2025)
Metric | Value | Detail |
Operating EBITDA | ₹15 Crore | First year of positive EBITDA |
Total Revenue | ₹234 Crore | ~$28M USD |
Global Hospital Network | 150,000+ | 180% Year-over-Year increase |
US User Base | 1 Million+ | Growing presence in dental and mental health |
US Monthly Active Users | 300,000 | Six-fold growth since launch |
Pre-IPO Valuation Target | $700 Million | Anticipated 2027 Listing |
India’s digital health infrastructure, centered on the Ayushman Bharat Digital Mission (ABDM), has provided a robust foundation for Practo’s growth. As of late 2025, over 834 million citizens hold ABHA digital IDs, and 787 million digital records have been linked. This interoperable system allows private entities like Practo to integrate seamlessly across the continuum of care, reducing the cost of custom API integrations and improving the velocity of innovation.
Practo's US expansion highlights its transition into a care navigation platform that utilises AI to enhance the patient experience. By focusing on high-intent categories such as dental and mental health, the company has successfully monetized over 500 doctors through paid subscriptions in the US, indicating that its model is portable across diverse regulatory and economic environments.
The Health AI X Factor and the Transition to Health Tech 2.0
The 2026 IPO cycle is defined by what Bessemer Venture Partners describes as the Health AI X Factor. This framework identifies a new generation of healthcare technology companies that demonstrate continuous hyper-growth velocity, revenue durability, and software-like margins at scale. Unlike the first generation of digital health companies, which were often viewed as tech-enabled services with low margins, the 2026 cohort is building agentic AI systems that can act independently on multi-step revenue and clinical processes.
Investment is increasingly concentrated in AI-powered clinical and revenue cycle management (RCM) solutions, hybrid care platforms, and interoperability infrastructure. Average deal sizes for health tech rounds increased by 42% between 2024 and 2025, reflecting a selective but high-conviction funding environment. Valuations for Series D and later-stage companies saw a 63% jump in the same period, driven primarily by Health AI deals.
Health Tech 2.0 vs. Traditional High-Growth Software (2025-2026)
Metric | Health Tech 2.0 Leaders | EMCLOUD (Nasdaq Cloud Index) |
Annualized Rev. Growth | 67% | 19% |
FCF Margin | 26%+ (Top Tier) | 5%-15% (Average) |
Rule of 40 (Growth + FCF) | 98+ (e.g., Hinge Health) | 30-40 (Average) |
EV / Annual Revenue | 5.7x - 13.8x | 7x - 12x |
Despite these superior metrics, the trust gap persists, partly due to the lackluster performance of early post-pandemic IPOs. However, as Health Tech 2.0 companies like Hinge Health and Tempus AI continue to demonstrate sustainable high growth and improving profitability profiles, institutional skepticism is beginning to narrow. Hinge Health, which filed for an IPO in March 2025, reported $390 million in revenue with a net loss of only $12 million, signaling a prioritised path to profitability that public markets now demand.
Regional Insights: The Asia-Pacific and Australian Landscapes
The Asia-Pacific region is emerging as a critical growth frontier for HealthTech. In Singapore, Doctor Anywhere raised $65.7 million in its Series C round, one of the largest private funding events in Southeast Asia. The company, founded in 2015, offers a range of healthcare solutions from telehealth to physical clinics and specialists. Its revenue grew by 61.8% in 2022 to $51.6 million, although losses widened as it invested in regional expansion and acquisitions, such as the taking private of Catalist-listed AHS.
In Australia, the IPO market showed tentative signs of recovery in 2025, with conditions setting the stage for a stronger environment in 2026. While the average amount raised per IPO declined, activity remained resilient among small-cap listings. Healthengine and HotDoc are the dominant players in the Australian appointment booking space. HotDoc, founded in 2012, has secured a broad base of over 21,000 practitioners and 9 million patients, positioning it as the country’s largest patient engagement platform. Healthengine, which raised AU$26.7 million in a round led by Sequoia India, serves one million Australians monthly and is focused on building a powerful health experience platform.
Advertiser | Share of Clicks (%) | Primary Focus/Incentive |
15.83% | Financial incentives (e.g., 12 weeks free) | |
10.20% | Same-day GP appointments and accessibility | |
7.59% | National network and local presence | |
5.85% | Rapid telehealth and prescription access | |
4.94% | Integrated insurance and care delivery | |
Others | 55.59% | Diverse specialized services |
The Australian market is also witnessing the emergence of AI-native firms like Firmus Technologies, which achieved a significant valuation in late 2025. The Australian Securities and Investment Commission (ASIC) and ASX Ltd. are currently testing a shortened IPO process to encourage more quality businesses to engage with public markets in 2026.
The Revenue Cycle Revolution: From Assistance to Autonomous Action
The most transformative trend in revenue cycle management (RCM) in 2026 is the shift toward agentic AI systems that can reason through multi-step processes without manual intervention. High-volume specialties such as radiology and pathology are leading this adoption, allowing human coders to shift toward quality assurance and compliance oversight. This transition is essential for HealthTech platforms looking to IPO, as it allows them to demonstrate the "glass box" interpretability required by new regulations like the EU AI Act.
Revenue integrity teams are now managing the entire claim lifecycle, from intake to payment, rather than focusing on accounts receivable after problems occur. This shift is driven by the reality that practices still relying on paper statements experience 20% to 30% slower collection cycles than their digital-first peers.
Top Healthcare BPO and RCM Companies (2026 Rankings)
Rank | Company | Services | Implementation Speed |
1 | Insignia Resources | Satellite staffing, pan-US oversight | 2-3 Weeks |
2 | R1 RCM | End-to-end RCM automation | 8-12 Weeks |
3 | Optum (Insight) | Data, analytics, integrated care | Large-scale integration |
4 | Conifer Health | Revenue integrity, A/R management | 10-14 Weeks |
5 | Accenture Health | Strategic partnerships, global delivery | Global scale |
The winning approach in 2026 is denial prevention. Providers are investing in stronger front-end verification and specialty-specific rules to counter the increasingly sophisticated automated denial engines deployed by payers. As payers issue batch denials within hours rather than days, HealthTech platforms that can predict and correct claim errors autonomously are seeing significant demand.
Technical Foundations: The Unified Platform Advantage
In 2026, the demand for unified or integrated healthcare platforms has surpassed interest in isolated point solutions. A unified platform connects EHRs, patient experience, practice management, and RCM into a single system layer where data moves in real time. This integration reduces revenue leakage and helps busy ambulatory clinics manage rising costs and staff burnout. Clinics that move to these unified systems see fewer hand-offs, fewer denials, and more predictable revenue.
Interoperability standards, such as FHIR R4/R5 and TEFCA, have moved from voluntary encouragement into mandatory enforcement in 2026. Data liquidity is now seen as the primary lever for innovation velocity. Platforms like Anolla have demonstrated that AI-driven triage and smart schedule optimisation can increase appointment completion rates on mobile by 22% to 25%.
Comparison of Leading Healthcare Platforms (2026)
Platform | Core Strength | Target Market |
AthenaOne | Integrated EHR, billing, and engagement | Large medical groups |
SimplePractice | All-in-one practice management | Health and wellness professionals |
Healthie | HIPAA-compliant EHR and engagement | Digital health startups and clinics |
Anolla | AI-driven triage and smart scheduling | Private clinics and diagnostic centers |
Jane Software | Customizable charting and online booking | Allied health and small practices |
CharmHealth | AI-native documentation and medical billing | Diverse practice sizes |
The technical stack of these platforms has also evolved to support the demands of real-time clinical operations. HotDoc, for instance, utilizes a modern containerized infrastructure with Docker, Ruby, and Python, supported by Grafana for analytics and Cloudflare for content delivery. This shift toward high-availability, API-first architectures allows for the rapid deployment of telehealth and patient communication tools that are essential for maintaining market leadership.
Investor Sentiment and the "American Accent" in Global Funding
A defining trend of 2026 is the strategic export of European innovation to the United States. US investors are identifying best-in-class European technologies and funding them specifically to scale on American soil. These ventures often arrive with deeper clinical validation than US-born startups, which were frequently raised in growth-at-all-costs environments.As a result, American capital participated in 62% of late-stage European deals in 2025, triple the rate seen in 2023.
This flood of capital into Europe raises questions about whether valuations are outpacing the region's limited exit infrastructure. However, the strategic value of Europe as a high-quality R&D engine for navigating FDA scrutiny and demanding US payers is undeniable. If European category winners like Doctolib can deliver public exits that justify American-style pricing, the region will cement its status as a true peer to the US.
Digital Health Venture Funding by Region (2025 YoY Growth)
Region | Funding Growth (%) | 2025 Total (USD) | Driver |
Europe | +15% | $6.2 Billion | US underwriting and TechBio focus |
APAC | +14% | $2.4 Billion | India’s infrastructure and SE Asia recovery |
Middle East | +11% | Small Base | Emerging digital wellness programs |
North America | +7% | $19.5 Billion | Maturity and concentration in AI-native assets |
Investor sentiment in 2026 remains selective. While funding is rising, it is increasingly concentrated into operational winners that can demonstrate unit economics and high retention rates. The age of selling on vision has ended; to raise capital or exit in 2026, ventures must satisfy procurement committees with establishes distribution and measurable operating outcomes.
The Unicorn Class of 2026: Sector Bellwethers
The private market continues to produce highly valued entities that serve as indicators for the broader HealthTech IPO pipeline. Devoted Health, for instance, has reached a $13 billion valuation by combining health insurance with coordinated care teams. Abridge, the poster child for generative AI in healthcare, boosted its valuation to $5.3 billion in mid-2025 following a $300 million Series E.
Selected Health Care Unicorns (2026 Watchlist)
Company | Valuation | Amount Raised | Focus Area |
Devoted Health | $13 Billion | $2.3 Billion | Medicare Advantage and virtual care |
Oura | $11 Billion | $1.0 Billion | Prevention and preventative health platform |
Cityblock Health | $6 Billion | $891.3 Million | Value-based care for underserved populations |
Abridge | $5.3 Billion | $757.5 Million | GenAI-powered clinical documentation |
Sword Health | $4 Billion | $493.5 Million | AI-driven musculoskeletal care |
Spring Health | $3.3 Billion | $466.5 Million | Employer-focused mental health |
The performance of these unicorns in the private secondary markets provides a real-time signal of IPO readiness. Companies like Maven Clinic and Ro have made senior hires with deep IPO experience, suggesting that preparations for 2026 and 2027 listings are well underway. Furthermore, the success of early 2026 listings, such as Belgium’s Agomab Therapeutics on the Nasdaq, has served as a bellwether, confirming that investor appetite for de-risked European assets has returned.
Strategic Implications and Future Outlook
The 2026 wave of HealthTech IPOs represents more than a period of market recovery; it is a fundamental shift in the definition of high-performance in digital health. The convergence of industrial-grade financial metrics, agentic AI deployment, and global infrastructure development (like India’s ABDM) has created a robust environment for category leaders to seek public liquidity.
For ZocDoc, the path forward involves leveraging its cash-flow-positive status to lead the transition to consumer-driven, AI-enabled patient navigation. For Doctolib, the challenge is to harmonize its European champion status with the valuation multiples available in US capital pools while maintaining its aggressive path toward a multi-billion dollar listing. For Practo, the success of its US expansion and its achievement of operating EBITDA profitability in India provide a blueprint for other emerging market HealthTech platforms looking to achieve global scale.
The central test heading into 2027 will be whether the ecosystem can generate exits that justify increasingly American-style pricing in a fragmented global regulatory landscape.
With over 30 to 35 biotech and healthtech IPOs expected globally in late 2026 and early 2027, the sector is poised for its most significant era of transformation since the onset of the digital health revolution.
The focus on durability, profitability, and measurable clinical outcomes ensures that the companies reaching the public markets in this wave are built for long-term relevance rather than just pandemic-era speed.
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
